CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Microgravity R&D
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

UChicago Medicine

Marita Kametas, MSN, APN, FNP-BC, CMSRN, COCN, Manager of Gastroenterology Advanced Practice Provider Services

Language in the Care of Patients with Inflammatory Bowel Disease: Who Failed?

Marita Kametas

Marita Kametas

Patient Language Advocate

As an advanced practice provider serving patients with inflammatory bowel disease, I am often struck by the language used within their healthcare journey.


Language and inference can inform patients' attitudes, perspectives, and the way they will interact with healthcare in the future. This language may seem insignificant, but the schema of our vernacular can inform not only the patient’s view of the care team but also their view of themselves and their journey alongside a chronic disease.


This can be seen quite clearly when we discuss patients who have previously been exposed to medical therapies that have been ineffective at controlling their disease. A common case presentation can sound like, “Ms. Smith is a 26-year-old Crohn’s patient who has failed infliximab, ustekinumab, and adalimumab and presents today to review other therapy options.” How we discuss the ineffectiveness of medications can often leave the patient questioning if they failed medications or the medications failed them. Fine-tuning the language we use surrounding medical therapies can support the care of the patient as a whole person beyond their inflammatory burden.


When we frame treatment experience as a failure, we risk impacting patients’ self-efficacy. The way we structure our sentences matters. There is a paucity of data evaluating the impact of language in the treatment of IBD; however, in my clinical experience, the use of negative language reinforces the negative stigma the patient may already feel about their disease process. Sometimes, this is a stigma the patient may not openly share with the care team. This can manifest as hesitance to try other advanced therapies or anxiety or depression related to their diagnosis and treatment.


Language and inference can inform patient attitudes, perspectives and the way they will interact with healthcare in the future.


So, it bears the question, could a simple rearrangement of a few words positively impact the patient’s view of their disease and treatment? Leaning into what we know about trauma related to chronic disease experiences may help to answer this question. Some qualitative research has shown that patients who are met with language that is alarming or negative carry that with them, and it can impact how they view their disease in the future. This can also rupture the therapeutic relationship between healthcare professionals and patients.


This can also be extrapolated to the way surgery is discussed with patients.


Speaking about surgery as a last resort or a failure can leave the patient feeling vulnerable and frightened. It is the provider’s responsibility to review surgical options as another tool in the treatment toolbox as opposed to a last resort. Surgery can lead to many fears about body image, scars, complications and the creation of an ostomy. An aim of treatment should be to lessen the burden of disease by addressing these fears and leveraging our language to support this. Using supportive language may aid in the mitigation of trauma related to diagnosis and treatment.


Language can undermine our therapeutic relationship with patients, or it can cement its foundation. A strong foundation with the care team supports the patient through flares and remission. Through this support, we may lessen the burden of living alongside inflammatory bowel disease for our patients and create a more positive patient-centered treatment landscape. Chronic inflammatory disease is the constant companion patients never asked for; failure does not have to be.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

For patients living with inflammatory bowel disease, clinical language can influence far more than understanding, shaping confidence, emotional well-being and trust in the care team. Kametas highlights why thoughtful communication around treatment response and surgery should be considered an essential part of compassionate, patient-centered care.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    UPS [NYSE:UPS]

    Four Myths about Innovation in Logistics

    Daniel Gagnon, Vice President, Global Healthcare Strategy and Marketing

  • Willis Towers Watson

    Veracyte, Inc [NASDAQ: VCYT]

    Leveraging Genomics for Personalised Healthcare

    Martin Bostrup, Executive Director, Market Access & Medical Affairs, EMEA

  • Willis Towers Watson

    Biogen [NASDAQ: BIIB]

    AI and Pharma Industry

    Alejandro Bagliano, Latam South Medical Affairs Head

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/leadership-perspective/language-in-the-care-of-patients-with-inflammatory-bowel-disease-who-failed-nwid-3792.html